<code id='9FCD021CFE'></code><style id='9FCD021CFE'></style>
    • <acronym id='9FCD021CFE'></acronym>
      <center id='9FCD021CFE'><center id='9FCD021CFE'><tfoot id='9FCD021CFE'></tfoot></center><abbr id='9FCD021CFE'><dir id='9FCD021CFE'><tfoot id='9FCD021CFE'></tfoot><noframes id='9FCD021CFE'>

    • <optgroup id='9FCD021CFE'><strike id='9FCD021CFE'><sup id='9FCD021CFE'></sup></strike><code id='9FCD021CFE'></code></optgroup>
        1. <b id='9FCD021CFE'><label id='9FCD021CFE'><select id='9FCD021CFE'><dt id='9FCD021CFE'><span id='9FCD021CFE'></span></dt></select></label></b><u id='9FCD021CFE'></u>
          <i id='9FCD021CFE'><strike id='9FCD021CFE'><tt id='9FCD021CFE'><pre id='9FCD021CFE'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:9

          A new Ebola epidemic in the Democratic Republic of the Congo is shaping up to be the most dangerous and difficult test of the world’s ability to contain the disease since the catastrophic West African outbreak in 2014 and 2015. What challenges are responders facing? And how might experimental vaccines be used to try to slow the spread of the epidemic?

          See below for an archived chat with Helen Branswell about these issues and more. 

          advertisement

          knowledge

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Novo Nordisk to buy Cardior, building up pipeline of heart drugs
          Novo Nordisk to buy Cardior, building up pipeline of heart drugs

          LISELOTTESABROE/Scanpix/AFPviaGettyImagesLONDON—NovoNordisksaidMondayitwouldacquiretheGermanfirmCard

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Paxlovid study fails to answer questions over benefit for broader groups

          KobiWolf/BloombergPfizersaidTuesdaythatamuch-watchedstudyofitsantiviralPaxlovidinpatientswhohaveCovi